Results 151 to 160 of about 1,327 (186)
Some of the next articles are maybe not open access.
Drugs, 2020
The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment
exaly +3 more sources
The orally disintegrating tablet (ODT) formulation of rimegepant (NURTEC ODT®) is a small molecule, highly-selective, calcitonin gene-related peptide antagonist that was developed by Biohaven Pharmaceutical Holding Company Ltd as an acute treatment for migraine. A conventional tablet formulation of the drug is being investigated for the acute treatment
exaly +3 more sources
Expert Review of Neurotherapeutics
Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity ...
William Wells-Gatnik +2 more
exaly +3 more sources
Rimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity ...
William Wells-Gatnik +2 more
exaly +3 more sources
Rimegepant oral disintegrating tablet for migraine
Lancet, The, 2019Lars Edvinsson
exaly +3 more sources
Rimegepant: Acute Treatment for Migraine Headaches
Pain Management, 2021Migraine headache treatment is quickly evolving. There have been three new acute migraine treatment options (i.e., lasmiditan, rimegepant, ubrogepant) and four new preventive migraine treatment options (i.e., erenumab, fremanezumab, galcanezumab, eptinezumab) released in the past 3 years.
Golden L Peters, Erin K Hennessey
openaire +2 more sources
Rimegepant for the treatment of migraine
Drugs of Today, 2020Rimegepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist developed with a novel quick-dissolve oral tablet formulation for the acute treatment of migraine by Biohaven Pharmaceuticals, under license from Bristol Myers Squibb. The completed phase II and III trials showed its efficacy in terms of pain freedom, pain relief, release ...
Negro A., Martelletti P.
openaire +2 more sources
Testing rimegepant for migraine—time to revise the trial design? – Authors' reply
Lancet, The, 2020Richard B Lipton
exaly +3 more sources
Rimegepant for the prevention and treatment of migraine
Prescriber, 2023Rimegepant (Vydura) is an oral CGRP inhibitor for the treatment of acute migraine and prevention of episodic migraine. This article discusses its indications, dosing and clinical trial outcomes.
openaire +1 more source
Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review
Annals of Pharmacotherapy, 2020Objective To review the pharmacology, pharmacokinetics, efficacy, safety, and place in therapy of rimegepant for treatment of migraine. Data Sources A comprehensive PubMed and Cochrane search (1985 to May 2020) was performed utilizing the keywords rimegepant, Nurtec, orally disintegrating tablet, migraine, migraine headache, migraine disorder ...
Alicia Potter DeFalco +2 more
openaire +2 more sources